Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 5:01 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 331 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Pelvic Malignancies Clear all
Recruiting Phase 2 Interventional

Abi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate Cancer

NCT07237269
View directory record Official record
Conditions
Prostate Cancer
Interventions
Androgen Deprivation Therapy (ADT), Abiraterone, Prednisone, Radiation Therapy
Drug · Radiation
Lead sponsor
University of Nebraska
Other
Eligibility
30 Years and older · Male only
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Nov 15, 2026, 5:01 AM EST
Completed Phase 2 Interventional Results available

Gemcitabine, Paclitaxel, Doxorubicin in Metastatic or Unresectable Bladder Cancer With Decreased Kidney Function

NCT00478361
View directory record Official record
Conditions
Distal Urethral Cancer, Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter, Proximal Urethral Cancer, Recurrent Bladder Cancer, Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter, Recurrent Urethral Cancer, Regional Transitional Cell Cancer of the Renal Pelvis and Ureter, Stage III Bladder Cancer, Stage IV Bladder Cancer, Transitional Cell Carcinoma of the Bladder, Urethral Cancer Associated With Invasive Bladder Cancer
Interventions
Gemcitabine hydrochloride, Paclitaxel, Doxorubicin hydrochloride, Pegfilgrastim
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
2
States / cities
Springfield, Missouri • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 9, 2020 · Synced Nov 15, 2026, 5:01 AM EST
Active, not recruiting No phase listed Observational

Changes in Pelvic Health, Sexual Function, and Quality of Life in Women With Pelvic Cancer Undergoing Radiation Therapy

NCT04713618
View directory record Official record
Conditions
Anal Carcinoma, Cervical Carcinoma, Endometrial Carcinoma, Malignant Pelvic Neoplasm, Rectal Carcinoma, Vaginal Carcinoma, Vulvar Carcinoma
Interventions
Pelvic Examination, Survey
Procedure · Other
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Nov 15, 2026, 5:01 AM EST
Recruiting Phase 2Phase 3 Interventional

Dose Optimization and Diagnostic Performance in Prostate Cancer (SPARROW [Staging Prostate Cancer With Advanced RM2 Radiotracer Oncologic Workup])

NCT07831824
View directory record Official record
Conditions
Prostate Cancer
Interventions
[68Ga]-LNTH-2401
Drug
Lead sponsor
Lantheus Medical Imaging
Industry
Eligibility
18 Years and older · Male only
Enrollment
408 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Grand Rapids, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Nov 15, 2026, 5:01 AM EST
Recruiting Not applicable Interventional

Intraoperative Neuromonitoring of Sacral Reflexes to Predict Post Operative Function in Patients Undergoing Sacrectomy for Pelvic Bone Malignancy or Patients Undergoing Spinal Procedures Without Sacral Root Involvement

NCT07707024
View directory record Official record
Conditions
Bone Neoplasm, Metastatic Malignant Neoplasm in the Bone
Interventions
Intraoperative Nerve Monitoring, Surgical Procedure, Survey Administration
Procedure · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2029
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Nov 10, 2026 · Synced Nov 15, 2026, 5:01 AM EST
Recruiting Phase 2 Interventional

Pembrolizumab and Enfortumab Vedotin With Pembrolizumab Prior to and After Radical Nephroureterectomy for High-Risk Upper Tract Urothelial Cancer

NCT05775471
View directory record Official record
Conditions
Renal Pelvis and Ureter Urothelial Carcinoma
Interventions
Biopsy, Biospecimen Collection, Enfortumab Vedotin, MR Urography, Nephroureterectomy, Pembrolizumab
Procedure · Drug · Biological
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Nov 15, 2026, 5:01 AM EST
Terminated Phase 1Phase 2 Interventional

A Phase I/II Trial of AEZS-108 in Urothelial Cancer Patients Who Failed Platinum-chemotherapy

NCT01234519
View directory record Official record
Conditions
Urothelial Carcinoma
Interventions
AEZS-108, AEZS-108 at MTD
Drug
Lead sponsor
AEterna Zentaris
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
2
States / cities
Miami, Florida • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 15, 2018 · Synced Nov 15, 2026, 5:01 AM EST
Completed Early Phase 1 Interventional

Pilot Study: Androgen Deprivation Therapy Impact on PSMA-PET Sensitivity in Prostatectomy Staging

NCT07069465
View directory record Official record
Conditions
Prostate Cancer
Interventions
flotufolastat F 18, Relugolix 120 MG, Serum PSA and Testosterone
Diagnostic Test · Drug
Lead sponsor
Urology Clinics of North Texas
Network
Eligibility
Male only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 16, 2025 · Synced Nov 15, 2026, 5:01 AM EST
Recruiting Phase 1Phase 2 Interventional

RYZ711 Diagnostic Platform Study

NCT07862582
View directory record Official record
Conditions
Prostate Cancer (Adenocarcinoma), Adenocarcinoma of the Prostate, Metastatic Castration-resistant Prostate Cancer (mCRPC), Metastatic Hormone-Sensitive Prostate Cancer (mHSPC), Biochemical Recurrence (BCR), High-Risk Localized Prostate Cancer
Interventions
RYZ711, PSMA PET/CT
Drug · Diagnostic Test
Lead sponsor
RayzeBio, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Nov 12, 2026 · Synced Nov 15, 2026, 5:01 AM EST
Recruiting Phase 1 Interventional

Nelfinavir, Cisplatin, and External Beam Radiation Therapy for the Treatment of Locally Advanced Vulvar Cancer That Cannot Be Removed by Surgery

NCT04169763
View directory record Official record
Conditions
Stage II Vulvar Cancer AJCC v8, Stage III Vulvar Cancer AJCC v8, Stage IIIA Vulvar Cancer AJCC v8, Stage IIIB Vulvar Cancer AJCC v8, Stage IIIC Vulvar Cancer AJCC v8, Stage IVA Vulvar Cancer AJCC v8
Interventions
Cisplatin, External Beam Radiation Therapy, Nelfinavir
Drug · Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 10, 2026 · Synced Nov 15, 2026, 5:01 AM EST
Completed Not applicable Interventional

Radiation or Observation Only in Endometrial Cancer Who Have Undergone Surgery

NCT00002807
View directory record Official record
Conditions
Endometrial Cancer
Interventions
radiation therapy
Radiation
Lead sponsor
NCIC Clinical Trials Group
Network
Eligibility
Up to 120 Years · Female only
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2009
U.S. locations
1
States / cities
Duluth, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 6, 2020 · Synced Nov 15, 2026, 5:01 AM EST
Completed Phase 2 Interventional Results available

A Phase II Study of AZD4877 (a Novel Anti-mitotic Agent) in Advanced Bladder Cancer

NCT00661609
View directory record Official record
Conditions
Bladder Cancer, Transitional Cell Bladder Cancer, Urethra Cancer, Ureter Cancer, Renal Pelvis Cancer
Interventions
AZD4877
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
18
States / cities
Palo Alto, California • San Bernardino, California • Southington, Connecticut + 15 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2011 · Synced Nov 15, 2026, 5:01 AM EST
Active, not recruiting Phase 4 Interventional

Registry of Sarcoma Patients Treated With Permanently Implantable LDR CivaSheet®

NCT04033081
View directory record Official record
Conditions
Sarcoma
Interventions
CivaSheet
Device
Lead sponsor
CivaTech Oncology
Industry
Eligibility
Not listed
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2030
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Nov 15, 2026, 5:01 AM EST
Terminated Phase 2 Interventional Results available

A Phase II Study of Extended Field IMRT External Beam Irradiation and Intracavitary Brachytherapy

NCT00590967
View directory record Official record
Conditions
Cervical Cancer
Interventions
IMRT extended field external beam radiation therapy, Brachytherapy, Cisplatin
Radiation · Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2013
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 29, 2016 · Synced Nov 15, 2026, 5:01 AM EST
Completed Phase 1 Interventional

Chemotherapy Plus Radiation Therapy in Treating Patients With Unresectable, Residual, or Recurrent Colorectal Cancer

NCT00003704
View directory record Official record
Conditions
Cancer
Interventions
capecitabine, radiation therapy
Drug · Radiation
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2003
U.S. locations
17
States / cities
Scottsdale, Arizona • Urbana, Illinois • Cedar Rapids, Iowa + 14 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2016 · Synced Nov 15, 2026, 5:01 AM EST
Completed Phase 2 Interventional Results available

Robotic-Assisted Laparoscopic Extended Pelvic Lymph Node Dissection for Transitional Cell Carcinoma of the Bladder

NCT00963859
View directory record Official record
Conditions
Bladder Cancer
Interventions
Robotic-assisted laparoscopic surgery
Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 21, 2013 · Synced Nov 15, 2026, 5:01 AM EST
Recruiting Not applicable Interventional

Stereotactic Magnetic Resonance Guided Radiation Therapy

NCT04115254
View directory record Official record
Conditions
Pancreas Cancer, Lung Cancer, Renal Cancer, Adrenal Metastases, Prostate Cancer, Liver Metastases, Oligoprogressive Nodal Metastases, Metachronous Nodal Metastases, Synchronous Nodal Metastases, Mesothelioma, Spine Metastases, Brain Metastases, Borderline Resectable Pancreatic Carcinoma
Interventions
MR-guided Linac
Radiation
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
397 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 13, 2025 · Synced Nov 15, 2026, 5:01 AM EST
Terminated Phase 2 Interventional Results available

Gemcitabine for the Prevention of Intravesical Recurrence of Urothelial Cancer in Patients With Upper Urinary Tract Urothelial Cancer Undergoing Radical Nephroureterectomy, GEMINI Study

NCT04398368
View directory record Official record
Conditions
Stage 0a Renal Pelvis and Ureter Cancer AJCC v8, Stage 0a Renal Pelvis Cancer AJCC v8, Stage 0a Ureter Cancer AJCC v8, Stage 0is Renal Pelvis and Ureter Cancer AJCC v8, Stage 0is Renal Pelvis Cancer AJCC v8, Stage 0is Ureter Cancer AJCC v8, Stage I Renal Pelvis and Ureter Cancer AJCC v8, Stage I Renal Pelvis Cancer AJCC v8, Stage I Ureter Cancer AJCC v8, Stage II Renal Pelvis and Ureter Cancer AJCC v8, Stage II Renal Pelvis Cancer AJCC v8, Stage II Ureter Cancer AJCC v8, Stage III Renal Pelvis and Ureter Cancer AJCC v8, Stage III Renal Pelvis Cancer AJCC v8, Stage III Ureter Cancer AJCC v8, Stage IV Renal Pelvis and Ureter Cancer AJCC v8, Stage IV Renal Pelvis Cancer AJCC v8, Stage IV Ureter Cancer AJCC v8
Interventions
Gemcitabine Hydrochloride
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
4
States / cities
Jacksonville, Florida • Rochester, Minnesota • Winston-Salem, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2023 · Synced Nov 15, 2026, 5:01 AM EST
Active, not recruiting Phase 2 Interventional

Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial Cancer

NCT03237780
View directory record Official record
Conditions
Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma, Locally Advanced Ureter Urothelial Carcinoma, Locally Advanced Urethral Urothelial Carcinoma, Metastatic Bladder Urothelial Carcinoma, Metastatic Renal Pelvis Urothelial Carcinoma, Metastatic Ureter Urothelial Carcinoma, Metastatic Urethral Urothelial Carcinoma, Recurrent Bladder Urothelial Carcinoma, Recurrent Renal Pelvis Urothelial Carcinoma, Recurrent Ureter Urothelial Carcinoma, Recurrent Urethral Urothelial Carcinoma, Stage III Bladder Cancer AJCC v8, Stage III Renal Pelvis Cancer AJCC v8, Stage III Ureter Cancer AJCC v8, Stage III Urethral Cancer AJCC v8, Stage IV Bladder Cancer AJCC v8, Stage IV Renal Pelvis Cancer AJCC v8, Stage IV Ureter Cancer AJCC v8, Stage IV Urethral Cancer AJCC v8, Unresectable Bladder Urothelial Carcinoma, Unresectable Renal Pelvis Urothelial Carcinoma, Unresectable Ureter Urothelial Carcinoma, Unresectable Urethral Urothelial Carcinoma
Interventions
Atezolizumab, Biopsy Procedure, Biospecimen Collection, Computed Tomography with Contrast, Eribulin Mesylate
Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
21
States / cities
Birmingham, Alabama • Buena Park, California • Duarte, California + 15 more
Source: ClinicalTrials.gov public record
Updated Nov 12, 2026 · Synced Nov 15, 2026, 5:01 AM EST
Completed Phase 3 Interventional Results available

An Ovarian, Primary Peritoneal or Fallopian Tube Cancer Study for Patients That Have Not Received Prior Chemotherapy

NCT00191646
View directory record Official record
Conditions
Genital Neoplasms, Female, Fallopian Tube Neoplasms, Ovarian Neoplasms, Pelvic Neoplasms, Peritoneal Neoplasms
Interventions
Gemcitabine, Paclitaxel, Carboplatin
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older · Female only
Enrollment
919 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2009
U.S. locations
54
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Los Gatos, California + 51 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2011 · Synced Nov 15, 2026, 5:01 AM EST
Completed Not applicable Interventional

Neoadjuvant Cetuximab, Fluorouracil, and Pelvic Irradiation in Treating Patients With Locally Advanced or Locally Recurrent Rectal Cancer

NCT00084773
View directory record Official record
Conditions
Colorectal Cancer
Interventions
cetuximab, fluorouracil, neoadjuvant therapy, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 120 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 22, 2015 · Synced Nov 15, 2026, 5:01 AM EST
Completed Phase 1Phase 2 Interventional

Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Bladder Cancer

NCT00003105
View directory record Official record
Conditions
Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter
Interventions
filgrastim, cisplatin, doxorubicin hydrochloride, gemcitabine hydrochloride, ifosfamide, paclitaxel
Biological · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2004
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 3, 2013 · Synced Nov 15, 2026, 5:01 AM EST
Completed Phase 3 Interventional Results available

The OLYMPUS Study - Optimized DeLivery of Mitomycin for Primary UTUC Study

NCT02793128
View directory record Official record
Conditions
Carcinoma, Transitional Cell, Transitional Cell Carcinoma of Renal Pelvis
Interventions
UGN-101 instillations
Drug
Lead sponsor
UroGen Pharma Ltd.
Industry
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
22
States / cities
Phoenix, Arizona • Loma Linda, California • Los Angeles, California + 17 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2020 · Synced Nov 15, 2026, 5:01 AM EST
Terminated Phase 2 Interventional Results available

Sorafenib in Treating Patients With Regional or Metastatic Cancer of the Urothelium

NCT00112905
View directory record Official record
Conditions
Adenocarcinoma of the Bladder, Distal Urethral Cancer, Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter, Proximal Urethral Cancer, Recurrent Bladder Cancer, Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter, Recurrent Urethral Cancer, Regional Transitional Cell Cancer of the Renal Pelvis and Ureter, Squamous Cell Carcinoma of the Bladder, Stage III Bladder Cancer, Stage IV Bladder Cancer, Transitional Cell Carcinoma of the Bladder, Urethral Cancer Associated With Invasive Bladder Cancer
Interventions
sorafenib tosylate, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 30, 2014 · Synced Nov 15, 2026, 5:01 AM EST